Optimizing Preclinical Model Selection and Next Generation Technology for CAR-T Cell Therapy Testing
Preclinical assessment of CAR-T cell therapies is challenging due to the lack of a single model to answer all efficacy- and safety-related questions. To maximize the success of each study, model choice should be carefully considered based on each model’s key advantages and limitations, alongside the aims of the study.
This White Paper presents the range of preclinical models available for CAR-T cell therapy evaluation and highlights their key utilities for assessing efficacy, toxicity, and target validation. A novel multiparameter imaging and analysis platform to detect and characterize CAR-T cells is also discussed, to enhance clinical development and success.
Download This White Paper to Understand:
- The pros and cons of preclinical models available for CAR-T cell therapy efficacy and safety assessment including xenograft, humanized, syngeneic, and transgenic models
- How to select and use patient-derived xenografts (PDX) expressing novel CAR targets to evaluate CAR-T cell therapies
- How a novel multiparameter imaging and analysis platform enables more highly sensitive detection of CAR-T cells compared to conventional approaches, and is used to determine clinical CAR-T cell persistence